六种治疗2型糖尿病的胰高血糖素样肽-1受体激动剂的药品临床综合评价  

Clinical comprehensive evaluation of 6 GLP-1RAs for treating type 2 diabetes mellitus

作　　者：谢泽宇 黄思咏 胡宵 李嘉宝 陈吉生[2] XIE Zeyu;HUANG Siyong;HU Xiao;LI Jiabao;CHEN Jisheng(Department of Pharmacy,Shenzhen Luohu People's Hospital,Guangdong Shenzhen 518000,China;Key Specialty of Clinical Pharmacy,First Affiliated Hospital,Guangdong Pharmaceutical University,Guangdong Guangzhou 510080,China)

机构地区：[1]深圳市罗湖区人民医院药学部,广东深圳518000 [2]广东药科大学附属第一医院临床药学重点专科,广东广州510080

出　　处：《中国医院药学杂志》2024年第24期2868-2875,共8页Chinese Journal of Hospital Pharmacy

基　　金：中央财政医疗服务与保障能力提升补助资金项目(编号:Z155080000004);深圳市三名工程项目(No.SZSM202301035);广东省第一批药品临床综合评价项目(编号:2022-1115-12);广州市民生科技攻关计划项目(编号:201803010096)。

摘　　要：目的:收集治疗2型糖尿病(T2DM)的胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)相关循证医学证据,以获得直观的临床综合评价结果,为医疗机构引进和合理使用GLP-1RA提供循证医学支持与参考。方法:通过文献研究和专家咨询法构建GLP-1RA治疗T2DM的药品临床综合评价指标体系。参考相关药品说明书,药品注册信息,英文数据库(PubMed、Embase和Cochrane Library),中文数据库(中国知网)有关GLP-1RA治疗T2DM的安全性、有效性、经济性、创新性、适宜性和可及性6个维度循证医学证据和研究对6种GLP-1RA进行客观评估。结果:本次评估的最终结果得分从高到低依次为:司美格鲁肽(85.10分)、度拉糖肽(79.25分)、利拉鲁肽(76.85分)、聚乙二醇洛塞那肽(70.25分)、利司那肽(65.00分)和艾塞那肽(63.50分)。结论:根据评估结果,当医疗机构引进和临床合理使用GLP-1RAs时,可优先选择排名前3的司美格鲁肽、度拉糖肽和利拉鲁肽作为推荐药品。OBJECTIVE To collect relevant evidence of evidence-based medicine of GLP-1RAs for treating type 2 diabetes mellitus(T2DM)to obtain intuitive results of comprehensive clinical evaluations and provide evidence-based medical supports and references for the introduction and rational use of GLP-1RAs at healthcare institutions.METHODS A comprehensive clinical evaluation system of drugs with GLP-1RAs for treating T2DM was constructed through literature researching and expert consulting.Six GLP-1RAs were objectively evaluated with references to evidence-based medical evidence and studies of six dimensions of safety,efficacy,economy,innovation,appropriateness and accessibility of GLP-1RAs for treating T2DM in the relevant drug inserts,drug registrations,English databases(PubMed,Embase&Cochrane Library)and Chinese database(China National Knowledge Infrastructure,CNKI).RESULTS The final outcome scores were,in a descending order,semaglutide(85.10),dulaglutide(79.25),liraglutide(76.85),polyethylene glycol loxenatide(70.25),lixisenatide(65.00)and exenatide(63.50).CONCLUSION Based upon the evaluation results,when GLP-1RAs are introduced and rationally used clinically at healthcare organizations,Top three of semaglutide,dulaglutide and liraglutide are recommended drugs.

关 键 词：胰高血糖素样肽-1受体激动剂 医院卫生技术评估 医疗机构药品遴选 2型糖尿病 药品临床综合评价 

分 类 号：R977[医药卫生—药品]